### 4th February 2016

TMT

## Dassault Systèmes

### Price EUR69.81

| Bloomberg<br>Reuters<br>12-month High<br>Market Cap (EU<br>Ev (BG Estimate<br>Avg. 6m daily vo<br>3y EPS CAGR | DSY FP<br>DAST.PA<br>76.1 / 54.8<br>17,922<br>16,487<br>300.9<br>18.8% |        |              |       |  |
|---|--|--------|--------------|-------|--|
|   | 1 M  | 3 M    | 6 M 31/12/15 |       |  |
| Absolute perf.  | -5.4%  | -4.1%  | 0.1%         | -5.4% |  |
| Softw.& Comp.   | -5.1%  | -2.9%  | 1.4%         | -5.1% |  |
| DJ Stoxx 600  | -9.9%  | -12.9% | -17.5%       | -9.9% |  |
| YEnd Dec. (€m)  | 2014   | 2015e  | 2016e        | 2017e |  |
| Sales   | 2,294  | 2,822  | 3,161        | 3,480 |  |
| % change  |  | 23.0%  | 12.0%        | 10.1% |  |
| EBITDA  | 677  | 887    | 1,046        | 1,191 |  |
| EBIT  | 430.8  | 630.3  | 802.1        | 943.6 |  |
| % change  |  | 46.3%  | 27.3%        | 17.6% |  |
| Net income  | 486.3  | 632.2  | 729.8        | 822.9 |  |
| % change  |  | 30.0%  | 15.4%        | 12.8% |  |
|   | 2014   | 2015e  | 2016e        | 2017e |  |
| Operating margin  | 27.6   | 29.7   | 31.5         | 32.7  |  |
| Net margin  | 12.7   | 15.0   | 16.8         | 17.9  |  |
| ROE   | 9.8  | 13.0   | 14.4         | 15.1  |  |
| ROCE  | 22.6   | 33.9   | 44.9         | 59.7  |  |
| Gearing   | -27.6  | -43.8  | -56.7        | -67.5 |  |
| (€)   | 2014   | 2015e  | 2016e        | 2017e |  |
| EPS   | 1.88   | 2.43   | 2.79         | 3.15  |  |
| % change  | -  | 29.7%  | 14.9%        | 12.6% |  |
| P/E   | 37.2x  | 28.7x  | 25.0x        | 22.2x |  |
| FCF yield (%)   | 2.5%   | 4.2%   | 4.4%         | 4.8%  |  |
| Dividends (€)   | 0.43   | 0.45   | 0.52         | 0.61  |  |
| Div yield (%)   | 0.6%   | 0.6%   | 0.7%         | 0.9%  |  |
| EV/Sales  | 7.5x   | 5.8x   | 5.0x         | 4.3x  |  |
| EV/EBITDA   | 25.3x  | 18.6x  | 15.1x        | 12.7x |  |
| EV/EBIT   | 27.0x  | 19.6x  | 15.9x        | 13.3x |  |



## FY15 results slightly above our estimates, investments will weigh on the margin in 2016

Fair Value EUR65 (-7%)

SELL

This morning Dassault Systèmes reported FY15 results slightly above our expectations and ahead of the consensus average, posting Q4 revenues 6% above the top-end of the guidance range (o/w an est. 3% on fx) and a non-IFRS operating margin 1.8ppt above the group's projections. FY16 company guidance (sales up 6-7% lfl, op. margin up 0.2ppt to c. 31%) is below our ests. and embeds the impact of a more volatile economic environment and investments in R&D and sales channels, which will weigh on the operating margin. We expect a negative share price reaction in the short term.

### ANALYSIS

- FY15 results slightly above our expectations. For 2015, on a non-IFRS basis, revenues were up 23% (+12% non-IFRS at cc and an est. +7% lfl) to EUR2.877bn, while the operating margin was up 1ppt to 30.8%, and EPS rose 24% to EUR2.25. On a lfl basis, the non-IFRS operating margin was up 1.2ppt and new licence sales grew by 11%. These figures were slightly above our ests. (sales EUR2,859m, operating margin 30.7%, EPS EUR2.17) and ahead of the consensus average (sales EUR2,843m, operating margin 30.3%, EPS EUR2,23). The figures were also above the high-end of the company's guidance range (non-IFRS sales up c. 12% cc to EUR2,820-2,830m, non-IFRS operating margin of c. 30%, and a non-IFRS EPS of c. EUR2.20, all based on EUR/USD and EUR/JPY assumptions of 1.12 and 135, vs. actual rates of 1.11 and 134).
- **Q4 2015 details**. With non-IFRS IfI sales growth of 8% to EUR802.1m and a 35.8% non-IFRS op. margin (+3.3ppt) for Q4, Dassault Systèmes was 6% (o/w an est. 3% on fx) above the top-end of its sales target (+5%/+6% cc to EUR745-755m) and 1.8ppt ahead of its op. margin (c. 34%) goal. On the product side, sales were up 8% IfI for Catia (licence sales up double-digit), up 14% IfI for Enovia (increasing 3DExperience adoption), and up 11% cc (driven by maintenance) for SolidWorks, while other software products were up 6% IfI (solid performance of Simulia). At the geographical level, on a IfI basis, Europe was up 5% (tough comps), the Americas were up 9% (driven by North America) and Asia was up 12%. Finally, on a IfI basis, non-IFRS initial licence fees and recurring licence fees were respectively up 11% and 7% the latter being driven by strong growth in maintenance.
- **FY16 guidance below our forecast**. We consider the FY16 guidance (non-IFRS sales up 6-7% lfl to EUR2,980-3,010m based on double-digit lfl growth in new licence sales, non-IFRS op. margin up 0.2ppt to c. 31%, non-IFRS EPS up 7% to c. EUR2.40, based on EUR/USD and EUR/JPY of 1.14 and 130), is, restated from the fx assumptions we had so far (EUR/USD 1.09, EUR/JPY 131), 3% below our expectations for sales (BG est.: EUR3,163m or +9.5% at cc; consensus: EUR3,065m), and 0.5ppt behind our ests. on the non-IFRS op. margin (BG est.: 31.5%; consensus: 31.7%). The company anticipates a more back-end loaded year based on a volatile economic environment, while DS plans to accelerate investments in R&D and sales channels. For Q1 2016, DS expects non-IFRS sales up an est. 5-8% lfl to EUR685-695m (BG est.: EUR732m), a non-IFRS op. margin of 24-25% (-1.8ppt/-0.8ppt), and a non-IFRS EPS of EUR0.42-0.45 (-2%/+5%).

### VALUATION

- Dassault Systèmes' shares are trading at est. 15.9x 2016 and 13.3x 2017 EV/EBIT multiples.
- Net cash position on 31st December 2015 was EUR1,351.3m (net gearing: -39%).

### NEXT CATALYSTS

Analysts' meeting at 10.30am CET / 9.30am BST / 4.30am EDT in Paris (Pavillon Gabriel, 5 avenue Gabriel) – call +33 1 70 48 01 66 (France) or +44 20 34 27 19 07 (UK). Conference call at 3pm CET / 2pm BST / 9am EDT (Europe: +44 14 52 54 10 03; USA: +1 646 741 21 20).

Click here to download document



Analyst : Gregory Ramirez 33(0) 1 56 68 75 91 gramirez@bryangarnier.com Sector Team : Richard-Maxime Beaudoux Thomas Coudry Dorian Terral

## BRYAN, GARNIER & CO

## Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

| BUY | Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a |  |  |  |
|-----|---|--|--|--|
| Der | recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of |  |  |  |
|     | elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on       |  |  |  |
|     | will feature an introduction outlining the key reasons behind the opinion.  |  |  |  |
|     |   |  |  |  |

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

#### Distribution of stock ratings

BUY ratings 61,2%

NEUTRAL ratings 29,9%

SELL ratings 9%

# Research Disclosure Legend

| 1  | Bryan Garnier shareholding<br>in Issuer   | ling Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").  |     |
|----|---|--|-----|
| 2  | Issuer shareholding in Bryan<br>Garnier   | ng in Bryan The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.   |     |
| 3  | Financial interest  | A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report   |     |
| 4  | Market maker or liquidity provider  | A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer on<br>in any related derivatives.  |     |
| 5  | Lead/co-lead manager  | ager In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.   |     |
| 6  | Investment banking agreement  |  |     |
| 7  | Research agreement A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.  |  | No  |
| 8  | Analyst receipt or purchase of shares in Issuer   |  |     |
| 9  | Remuneration of analyst   | The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.  |     |
| 10 | Corporate finance client  | ate finance client In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.  |     |
| 11 | Analyst has short position The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer. |  | No  |
| 12 | Analyst has long position The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.   |  | No  |
| 13 | Bryan Garnier executive is<br>an officer  |  |     |
| 14 | Analyst disclosure  | The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report. | Yes |
| 15 | Other disclosures   | Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).   | No  |

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

## BRYAN, GARNIER & CO

| London                          | Paris                                     | New York                 | Geneva             | New Delhi            |
|---------------------------------|---|--------------------------|--------------------|----------------------|
| Beaufort House                  | 26 Avenue des Champs Elysées              | 750 Lexington Avenue     | rue de Grenus 7    | The Imperial Hotel   |
| 15 St. Botolph Street           | 75008 Paris                               | New York, NY 10022       | CP 2113            | Janpath              |
| London EC3A 7BB                 | Tel: +33 (0) 1 56 68 75 00                | Tel: +1 (0) 212 337 7000 | Genève 1, CH 1211  | New Delhi 110 001    |
| Tel: +44 (0) 207 332 2500       | Fax: +33 (0) 1 56 68 75 01                | Fax: +1 (0) 212 337 7002 | Tel +4122 731 3263 | Tel +91 11 4132 6062 |
| Fax: +44 (0) 207 332 2559       | Regulated by the                          | FINRA and SIPC member    | Fax+4122731 3243   | +91 98 1111 5119     |
| Authorised and regulated by the | Financial Conduct Authority (FCA) and     |                          | Regulated by the   | Fax +91 11 2621 9062 |
| Financial Conduct Authority     | the Autorité de Contrôle prudential et de |                          | FINMA              |                      |
| (FCA)                           | resolution (ACPR)                         |                          |                    |                      |

### Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm or an associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited and should not rely on it for any purposes whatsoever. Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..

## BRYAN, GARNIER & CO